Now in its 7th year, the World Bispecific Summit continues to help the community to develop more clinically successful bispecifics.
Uniquely positioned as the only meeting specifically focussed on bispecific therapeutics, the in-depth insights and case studies shared will enable you to accelerate the progression of your bispecific candidates into the clinic.
With over 80 bispecific formats currently in development, validating the appropriate approach to take is of paramount importance. The World Bispecific Summit enable you to enhance target identification, improve preclinical development, overcome manufacturing challenges and maximize clinical performance.
Incorporating insights from AbbVie, Amgen, Roche, MacroGenics and many more industry leading companies, this year’s meeting will drill down into the challenges holding back progress and provide clear actions to overcome these developmental hurdles.
“Very well organized conference and very focused on topics that matter. Top speakers. The best conference in the field in my opinion.”
“This meeting provided a very good, detailed and critical overview of the field of bispecific biologics.”
“World Bispecific Antibody Summit provides excellent mix of science and networking”